Global Autologous CAR-T Cell Therapy Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Autologous CAR-T Cell Therapy market size was valued at US$ 4566 million in 2024 and is forecast to a readjusted size of USD 17680 million by 2031 with a CAGR of 21.6% during review period.
CAR-T cell therapy is a novel immunotherapy method, abbreviated as chimeric antigen receptor T cells. Autologous CAR-T cell therapy uses the patient's own T cells, which are genetically engineered to express a specific receptor, thereby enhancing their ability to target tumor cells.
Cell immunotherapy techniques, represented by chimeric antigen receptor T-cell immunotherapy (CAR-T therapy), express CAR fusion proteins on the surface of T cells through genetic engineering technology. The CAR extracellular antigen recognition region (one of the components of CAR cells, responsible for recognizing tumor cell surface antigens) can specifically recognize tumor antigens and transmit signals into cells to activate T cells, achieving proliferation and targeted killing of tumor cells. CAR-T therapy has shown breakthrough efficacy and enormous potential for development and market prospects for cancer patients who are unable to cope with traditional treatments. CAR-T cells are divided into autologous and allogeneic CAR-T cells. At present, CAR-T therapy mainly uses autologous CAR-T cells.
In recent years, the progress of autologous CAR-T cell therapy in hematological tumors has inspired scientists to extend this technology to the treatment of solid tumors. However, the current progress in the treatment of solid tumors is relatively slow. But in the future, with the discovery of more targets and the development of clinical trials, solid tumors are expected to become the main treatment area for CAR-T. At present, JW (Cayman) Therapeutics is laying out more innovative products to officially enter the field of cell therapy for solid tumors.
This report is a detailed and comprehensive analysis for global Autologous CAR-T Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Autologous CAR-T Cell Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
Global Autologous CAR-T Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Autologous CAR-T Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Autologous CAR-T Cell Therapy market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Autologous CAR-T Cell Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Autologous CAR-T Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead (Kite Pharma), Bristol Myers Squibb, Fosun Kite Biotechnology, JW Therapeutics, Bluebird Bio, IASO Bio, Juventas Cell Therapy, Legend Biotech, CARsge, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Autologous CAR-T Cell Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Target: CD19
Target: BCMA
Market segment by Application
Hematological Tumors
Solid Tumor
Market segment by players, this report covers
Novartis
Gilead (Kite Pharma)
Bristol Myers Squibb
Fosun Kite Biotechnology
JW Therapeutics
Bluebird Bio
IASO Bio
Juventas Cell Therapy
Legend Biotech
CARsge
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Autologous CAR-T Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Autologous CAR-T Cell Therapy, with revenue, gross margin, and global market share of Autologous CAR-T Cell Therapy from 2020 to 2025.
Chapter 3, the Autologous CAR-T Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Autologous CAR-T Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Autologous CAR-T Cell Therapy.
Chapter 13, to describe Autologous CAR-T Cell Therapy research findings and conclusion.
CAR-T cell therapy is a novel immunotherapy method, abbreviated as chimeric antigen receptor T cells. Autologous CAR-T cell therapy uses the patient's own T cells, which are genetically engineered to express a specific receptor, thereby enhancing their ability to target tumor cells.
Cell immunotherapy techniques, represented by chimeric antigen receptor T-cell immunotherapy (CAR-T therapy), express CAR fusion proteins on the surface of T cells through genetic engineering technology. The CAR extracellular antigen recognition region (one of the components of CAR cells, responsible for recognizing tumor cell surface antigens) can specifically recognize tumor antigens and transmit signals into cells to activate T cells, achieving proliferation and targeted killing of tumor cells. CAR-T therapy has shown breakthrough efficacy and enormous potential for development and market prospects for cancer patients who are unable to cope with traditional treatments. CAR-T cells are divided into autologous and allogeneic CAR-T cells. At present, CAR-T therapy mainly uses autologous CAR-T cells.
In recent years, the progress of autologous CAR-T cell therapy in hematological tumors has inspired scientists to extend this technology to the treatment of solid tumors. However, the current progress in the treatment of solid tumors is relatively slow. But in the future, with the discovery of more targets and the development of clinical trials, solid tumors are expected to become the main treatment area for CAR-T. At present, JW (Cayman) Therapeutics is laying out more innovative products to officially enter the field of cell therapy for solid tumors.
This report is a detailed and comprehensive analysis for global Autologous CAR-T Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Autologous CAR-T Cell Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
Global Autologous CAR-T Cell Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Autologous CAR-T Cell Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Autologous CAR-T Cell Therapy market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Autologous CAR-T Cell Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Autologous CAR-T Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead (Kite Pharma), Bristol Myers Squibb, Fosun Kite Biotechnology, JW Therapeutics, Bluebird Bio, IASO Bio, Juventas Cell Therapy, Legend Biotech, CARsge, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Autologous CAR-T Cell Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Target: CD19
Target: BCMA
Market segment by Application
Hematological Tumors
Solid Tumor
Market segment by players, this report covers
Novartis
Gilead (Kite Pharma)
Bristol Myers Squibb
Fosun Kite Biotechnology
JW Therapeutics
Bluebird Bio
IASO Bio
Juventas Cell Therapy
Legend Biotech
CARsge
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Autologous CAR-T Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Autologous CAR-T Cell Therapy, with revenue, gross margin, and global market share of Autologous CAR-T Cell Therapy from 2020 to 2025.
Chapter 3, the Autologous CAR-T Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Autologous CAR-T Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Autologous CAR-T Cell Therapy.
Chapter 13, to describe Autologous CAR-T Cell Therapy research findings and conclusion.
Table of Contents
89 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
